Evidence map›Paper›PMID 41930162›Full record

ArticleOncology research2026

miR-100-5p Enhances Cell Cycle-Mediated Chemoresistance by Modulating the CTDSPL/pRB/E2F1 Signaling Pathway in Oxaliplatin-Resistant Colorectal Cancer Cells.

Yen-Pin Chen, Rathinasamy Baskaran, Hema Sri Devi, Chaouhan Hitesh Singh, Yu-Jung Lin, Marthandam Asokan Shibu, Wei-Wen Kuo, Shih-Chieh Liao, Ming-Cheng Chen, Tso-Fu Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yen-Pin ChenSchool of Medicine, National Defense Medical University, Taipei, Taiwan.
Rathinasamy BaskaranCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Hema Sri DeviCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Chaouhan Hitesh SinghCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Yu-Jung LinCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Marthandam Asokan ShibuDepartment of Biotechnology, Bharathiar University, Coimbatore, India.
Wei-Wen KuoDepartment of Biological Science and Technology, China Medical University, Taichung, Taiwan.
Shih-Chieh LiaoGraduate Institute of Chinese Medical Science, China Medical University, 91 Hsueh-Shih Road, Taichung, Taiwan.
Ming-Cheng ChenDepartment of Surgery, Division of Colorectal Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
Tso-Fu WangDepartment of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Chi-Cheng LiInternational Medical Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Tsung-Jung HoDepartment of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
Tzu-Ching ShihDepartment of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan.
Shinn-Zong LinBuddhist Tzu Chi Foundation Hospital, Hualien, Taiwan.
Chih-Yang HuangCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: MicroRNAs (miRNAs) are small, non-coding RNAs that play a key role in the development of chemoresistance in various cancer types, including colorectal cancer (CRC). In this study, we aimed to study the underlying mechanisms of miRNA in chemotherapy-resistant CRC. Methods: LoVo CRC cell line was exposed to oxaliplatin at an increased dose, and cells were cultured in the presence of oxaliplatin to develop LoVoOXR cells. Microarray and Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR), western blot, and transwell assay were used to evaluate the chemoresistance in LoVo Results: Microarray and qRT-PCR analysis showed an increased expression of miR-100-5p in LoVo Conclusions: miR-100-5p plays an oncogenic role in inducing chemoresistance through modulation of the CTDSPL/retinoblastoma protein (pRB)/E2F transcription factor 1 (E2F1) axis in CRC cells.

Indexed as

Colorectal NeoplasmsDrug Resistance, NeoplasmE2F1 Transcription FactorMicroRNAsPhosphoprotein PhosphatasesAntineoplastic AgentsApoptosisCell CycleCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansOxaliplatinSignal TransductionAntineoplastic AgentsE2F1 protein, humanE2F1 Transcription FactorMicroRNAsMIRN100 microRNA, humanOxaliplatinPhosphoprotein Phosphatasescell cycle progressionchemoresistancecolorectal cancersC-terminal domain small phosphatase-like (CTDSPL)/retinoblastoma protein (pRB)/E2F transcription factor 1 (E2F1)miR-100-5p

Identifiers

PMID41930162
PMCPMC13040292

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.